natgillin/translations-raw huggingface dataset:
Clopidogrel is extensively metabolised by the liver. 
Klopidogrel se obsežno presnovi v jetrih.
• kidney disease 
Žilne bolezni
What Clopidogrel/Acetylsalicylic acid Teva looks like and contents of the pack Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets are light pink to pink, film-coated capsule shaped tablets. 
Izgled zdravila Klopidogrel/acetilsalicilna kislina Teva in vsebina pakiranja Klopidogrel/acetilsalicilna kislina Teva 75 mg/100 mg filmsko obložene tablete so svetlo roza do roza, filmsko obložene tablete v obliki kapsule.
What Clopidogrel/Acetylsalicylic acid Teva looks like and contents of the pack Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets are yellow, film-coated capsule shaped tablets. 
Izgled zdravila Klopidogrel/acetilsalicilna kislina Teva in vsebina pakiranja Klopidogrel/acetilsalicilna kislina Teva 75 mg/75 mg filmsko obložene tablete so rumene, filmsko obložene tablete v obliki kapsule.
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug induced hypersentsitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
Zelo redki, neznana povzročen sindrom preobčutljivosti, kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS), eritematozen ali eksfoliativni izpuščaj, urtikarija, ekcem, lihen planus
Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg 
Klopidogrel/acetilsalicilna kislina Teva 75 mg/75 mg
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg 
Klopidogrel/acetilsalicilna kislina Teva 75 mg/100 mg
Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), talc, maltodextrin, medium chain triglycerides, iron oxide yellow (E172). 
Obloga tablete: hipromeloza, polidekstroza, titanov dioksid (E171), smukec, maltodekstrin, srednjeverižni trigliceridi, rumeni železov oksid (E172), karmin (E120),
With moderate intoxication an attempt can be made to induce vomiting; if this fails, gastric lavage is indicated. 
V primeru zmerne zastrupitve je mogoče poskusiti izzvati bruhanje.
Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), quinoline yellow aluminium lake (E104), talc, maltodextrin, medium chain triglycerides and iron oxide yellow (E172). 
Obloga tablete: hipromeloza, polidekstroza, titanov dioksid (E171), kinolinsko rumeno (E104), smukec, maltodekstrin, srednjeverižni trigliceridi in rumeni železov oksid
While you are taking Clopidogrel/Acetylsalicylic acid Teva: 
Ko jemljete zdravilo Klopidogrel/acetilsalicilna kislina Teva:
These may be the signs of an allergic reaction. 
To so lahko znaki
How to take Clopidogrel/Acetylsalicylic acid Teva 
Kako jemati zdravilo Klopidogrel/acetilsalicilna kislina Teva
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. 
Pri sočasni uporabi pantoprazola 80 mg/dan, so se zmanjšale plazemske koncentracije aktivnega presnovka za 20 % (začetni odmerek) in 14 % (vzdrževalni odmerek).
Repeated doses of clopidogrel 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7. 
Večkratni odmerki klopidogrela po 75 mg na dan so povzročili pomembno zaviranje z ADP sprožene agregacije trombocitov od prvega dne dalje.
Very rare, not known among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)* 
Zelo redki, neznana alergijskih simptomov alergije na hrano*, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4) *
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the group taking ASA alone. 
V študiji CLARITY je v skupini s klopidogrelom in z ASA prišlo do splošnega povečanja krvavitev v primerjavi z ASA.
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, gastro-duodenal ulcer/perforations*, 
Krvavitev v prebavila in retroperitonealna krvavitev s smrtnim izidom, pankreatitis, razjede/perforacije na želodcu/dvanajstniku*, kolitis (vključno z ulceroznim in limfocitnim kolitisom), simptomi zgornjih prebavil*,
Do not take Clopidogrel/Acetylsalicylic acid Teva 
Ne jemljite zdravila Klopidogrel/acetilsalicilna kislina Teva:
(psoriasis), 
• driska,
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid (ASA). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki hidrogensulfata) in 100 mg acetilsalicilne kisline (ASA).
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state). 
Študija je ocenjevala farmakokinetiko in antiagregacijski odziv po uporabi odmerka 300 mg in nato 75 mg/dan ter 600 mg in nato 150 mg/dan, vsakega skupaj 5 dni (stanje dinamičnega ravnovesja).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki hidrogensulfata) in 75 mg acetilsalicilne kisline (ASA).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4 »Možni neželeni učinki«).
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence 
Bolezni prebavil Krvavitev v prebavila, driska, bolečine v trebuhu, dispepsija in razjeda na dvanajstniku, gastritis, bruhanje, navzea, zaprtje, flatulenca
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information reported in published information for ASA (frequency “not known”). 
* Informacije, ki so v literaturi navedene za ASA (pogostnost »neznana«).
Breast-feeding should be discontinued during treatment with the combination of clopidogrel/acetylsalicylic acid. 
Med zdravljenjem s kombinacijo klopidogrela/acetilsalicilne kisline je treba dojenje prekiniti.
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid. 
Ena tableta vsebuje 75 mg klopidogrela (v obliki hidrogensulfata) in 75 mg acetilsalicilne
Eye disorders Ear and labyrinth disorders 
Ušesne bolezni, vključno z motnjami labirinta
Medium chain triglycerides Iron oxide yellow (E172) Carmine (E120) Iron oxide red (E172) 
Filmska obloga: hipromeloza 15 cP polidekstroza titanov dioksid (E171) smukec maltodekstrin srednjeverižni trigliceridi rumeni železov oksid (E172) karmin (E120) rdeči železov oksid (E172)
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid. 
Ena tableta vsebuje 75 mg klopidogrela (v obliki hidrogensulfata) in 100 mg acetilsalicilne
NAME OF THE MEDICINAL PRODUCT Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets 
IME ZDRAVILA Klopidogrel/acetilsalicilna kislina Teva 75 mg/100 mg filmsko obložene tablete
NAME OF THE MEDICINAL PRODUCT Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets 
IME ZDRAVILA Klopidogrel/acetilsalicilna kislina Teva 75 mg/75 mg filmsko obložene tablete
There is no information concerning overdose with the combination of clopidogrel/acetylsalicylic acid. 
O prevelikem odmerjanju kombinacije klopidogrela/acetilsalicilne kisline ni informacij.
• Hepatic impairment 
• želodčna razjeda,
• Severe hepatic impairment. 
• pri bolnikih s hudo okvaro ledvic,
• jaundice 
• zlatenica,
Anaphylactic shock*, serum sickness, anaphylactoid reactions, aggravation of allergic symptoms of food allergy*, cross-reactive drug hypersensitivity 
Bolezni imunskega sistema anafilaktični šok*, serumska bolezen, anafilaktoidne reakcije, poslabšanje
How to store Clopidogrel/Acetylsalicylic acid Teva 
Shranjevanje zdravila Klopidogrel/acetilsalicilna kislina Teva
What Clopidogrel/Acetylsalicylic acid Teva contains 
Kaj vsebuje zdravilo Klopidogrel/acetilsalicilna kislina Teva
System Organ 
Organski sistem Pogosti
Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets clopidogrel/acetylsalicylic acid 
Klopidogrel/acetilsalicilna kislina Teva 75 mg/75 mg filmsko obložene tablete klopidogrel/acetilsalicilna kislina
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki hidrogensulfata) in 100 mg acetilsalicilne kisline.
• stomach ulcer 
• Okvara jeter
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki hidrogensulfata) in 75 mg acetilsalicilne kisline.
Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid 
Klopidogrel/acetilsalicilna kislina Teva 75 mg/100 mg filmsko obložene tablete klopidogrel/acetilsalicilna kislina
You should stop other clopidogrel treatment while you are taking Clopidogrel/Acetylsalicylic acid Teva. 
Če se pojavi podaljšanje krvavitve v času jemanja zdravila Klopidogrel/acetilsalicilna kislina Teva
• fever 
• plod:
• burning in stomach and/or oesophagus 
• pekoč občutek v želodcu in/ali požiralniku,
The combination of clopidogrel/acetylsalicylic acid must not be used in patients with severe renal impairment (see section 4.3). 
Kombinacije klopidogrela/acetilsalicilne kisline se ne sme uporabljati pri bolnikih s hudo okvarjenim delovanjem ledvic (glejte poglavje 4.3).Terapevtske izkušnje pri bolnikih z blago do zmerno okvarjenim delovanjem ledvic so omejene (glejte poglavje 4.4).
Possible side effects 
Pomožne snovi
Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets Clopidogrel/Acetylsalicylic acid 
Klopidogrel/acetilsalicilna kislina Teva 75 mg/100 mg tablete klopidogrel/acetilsalicilna kislina
Contact your doctor immediately if you experience: • fever, signs of infection or extreme tiredness. 
• zvišana telesna temperatura, znaki okužbe ali huda utrujenost.
• dizziness 
• izpuščaji,
• constipation 
Vrtoglavica
NAME OF THE MEDICINAL PRODUCT Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg tablets Clopidogrel/Acetylsalicylic acid 
Klopidogrel/acetilsalicilna kislina Teva 75 mg/75 mg tablete klopidogrel/acetilsalicilna kislina
2 capsules 
2 kapsuli
1 capsule (125 mg) + 2 capsules (80 mg) 
1 kapsula (125 mg) + 2 kapsuli (80 mg)
1 sachet + 2 dispensers + 1 cap + 1 mixing cup 
kapsula, trda peroralna uporaba pretisni omot (PVC/alu) 1 kapsula kapsula, trda peroralna uporaba pretisni omot (PVC/alu) 6 x 1 kapsula prašek za peroralno suspenzijo peroralna uporaba vrečka (PET/Alu/LLDPE) 1 vrečka + 2 odmernika + 1 zaporka + 1 čaša za mešanje
The marketing authorisation holders should provide convincing and robust data to identify a patient population in which the clinical benefits of ketoconazole-containing products for oral use clearly outweigh the risks. 
Imetniki dovoljenja za promet z zdravilom morajo predložiti prepričljive in zanesljive podatke, ki bi omogočili določanje specifične populacije bolnikov, pri kateri klinične koristi zdravil za peroralno uporabo, ki vsebujejo ketokonazol, jasno odtehtajo z njimi povezana tveganja.
National Competent Authorities of Member State(s) or Reference Member State(s) if applicable, shall ensure that the following conditions are fulfilled by the MAH(s): 
Pristojni nacionalni organi ene ali več držav članic ali referenčnih držav članic bodo zagotovili, kadar je to primerno, da imetnik(i) dovoljenja za promet z zdravilom izpolnjuje(jo) naslednje pogoje:
Annex III Conditions for lifting the suspension of the Marketing Authorisation(s) 
Priloga III Pogoji za preklic začasnega umika dovoljenj za promet z zdravili
Conditions for lifting the suspension of the Marketing Authorisation(s) 
Pogoji za preklic začasnega umika dovoljenj za promet z zdravili
The company had not yet responded to the last round of questions at the time of the withdrawal. 
Družba v času umika še ni odgovorila na zadnja vprašanja.
The company also provided results of a mathematical (modelling and simulation) exercise to predict the levels of the active substances and the medicine's effectiveness in clearing the virus from the blood in different circumstances. 
Družba je priskrbela tudi rezultate matematičnih (modelnih in simulacijskih) operacij, da bi predvideli ravni zdravilnih učinkovin in učinkovitost zdravila pri odstranjevanju virusa iz krvi v različnih okoliščinah.
What is Cokiera? 
Kaj je zdravilo Cokiera?
The active substances in Cokiera work in different ways. 
Zdravilne učinkovine v zdravilu Cokiera različno delujejo.
The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated lists of questions. 
Vlogo so umaknili po tem, ko je odbor CHMP ocenil dokumentacijo, ki jo je predložila družba, in oblikoval seznam vprašanj.
Ritonavir itself does not have an antiviral effect on hepatitis C virus. 
Ritonavir sam po sebi nima protivirusnega učinka na virus hepatitisa C.
The active substances in Cokiera are effective against hepatitis C virus genotypes 1a and 1b. 
Zdravilne učinkovine v zdravilu Cokiera so učinkovite proti virusu hepatitisa C genotipov 1a in 1b.
On 3 August 2016, AbbVie Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Cokiera, for the treatment of chronic hepatitis C. 
Družba AbbVie Ltd je 3. avgusta 2016 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Cokiera, namenjenim zdravljenju kroničnega hepatitisa C.
Because all the active substances in Cokiera were already included in authorised medicines, the company presented the results of studies to see whether the active substances from Cokiera were ‘bioequivalent' to the authorised medicines. 
Ker so bile vse zdravilne učinkovine v zdravilu Cokiera že vključene v odobrena zdravila, je družba predstavila rezultate študij, da bi ugotovili, ali so zdravilne učinkovine v zdravilu Cokiera biološko enakovredne odobrenim zdravilom.
Cokiera is an antiviral medicine containing the active substances dasabuvir, ombitasvir, paritaprevir and ritonavir. 
Zdravilo Cokiera je protivirusno zdravilo, ki vsebuje zdravilne učinkovine dasabuvir, ombitasvir, paritaprevir in ritonavir.
Cokiera was expected to be used for treating adults with chronic (long-term) hepatitis C. Hepatitis C is an infection of the liver caused by the hepatitis C virus. 
Zdravilo Cokiera naj bi se uporabljalo za zdravljenje odraslih s kroničnim (dolgotrajnim) hepatitisom C. Hepatitis C je okužba jeter, ki jo povzroča virus hepatitisa C.
The CHMP considered that the data provided did not properly show how the size of meals affect absorption of the active substances from Cokiera and therefore how well Cokiera works. 
Presodil je, da predloženi podatki ne kažejo ustrezno, kako velikost obroka vpliva na absorpcijo zdravilnih učinkovin v zdravilu Cokiera in posledično učinkovitost zdravila Cokiera.
All four active substances in Cokiera are already available in authorised medicines for treating chronic hepatitis C. It was expected that combining the substances in a single tablet would make it simpler for patients to take their medicine. 
Vse štiri zdravilne učinkovine v zdravilu Cokiera se že uporabljajo v odobrenih zdravilih za zdravljenje kroničnega hepatitisa C. Kombiniranje učinkovin v eni tableti naj bi bolnikom olajšalo jemanje zdravila.
What was Cokiera expected to be used for? 
Za kaj naj bi se zdravilo Cokiera uporabljalo?
In its letter notifying the Agency of the withdrawal of application, the company stated that the withdrawal is based on strategic business reasons for this specific product. 
Družba je v dopisu, s katerim je agencijo obvestila o umiku vloge, navedla, da je vlogo umaknila zaradi strateških poslovnih razlogov v zvezi z zdravilom Cokiera.
Based on the review of the data at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Cokiera could not have been approved for the treatment of chronic hepatitis C in adults. 
Na podlagi pregleda podatkov je odbor v času umika izrazil določene zadržke in začasno menil, da zdravila Cokiera ni mogoče odobriti za zdravljenje kroničnega hepatitisa C pri odraslih.
The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for this specific product. 
Družba je odbor CHMP obvestila, da trenutno ne potekajo klinična preskušanja ali programi sočutne uporabe zdravila Cokiera.
Dasabuvir blocks the action of an enzyme in the hepatitis C virus, called ‘NS5B RNA-dependent polymerase', which the virus needs to multiply. 
Dasabuvir zavira delovanje encima v virusu hepatitisa C, imenovanega „RNK-polimeraza NS5B, odvisna od RNK“, ki ga virus potrebuje za razmnoževanje.
Ombitasvir blocks the action of a protein in the hepatitis C virus called ‘NS5A' and paritaprevir blocks the action of another protein called ‘NS3/4A', both of which the virus needs to multiply. 
Ombitasvir zavira delovanje beljakovine v virusu hepatitisa C, imenovane „NS5A“, paritaprevir pa zavira delovanje druge beljakovine, imenovane „NS3/4A“.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not provided enough data to support the application for Cokiera. 
Zato je v času umika menil, da družba ni predložila zadostnih podatkov v podporo vlogi za zdravilo Cokiera.
How is Cokiera expected to work? 
Kako naj bi zdravilo Cokiera delovalo?
Ritonavir, the fourth active substance, slows down the removal of paritaprevir from the body by blocking an enzyme called CYP3A that breaks down paritaprevir. 
telesa, tako da zavira encim CYP3A, ki razgrajuje paritaprevir.
Generally, these reactions were mild or moderate. 
Te reakcije so bile na splošno rečeno blage ali zmerne.
Cmax was not significantly changed. 
Cmax se ni signifikantno spremenila.
Do not give this medicine to children and adolescents under the age of 18 because the potential risks and benefits are not known. 
Tega zdravila ne dajajte otrokom in mladostnikom, ki so mlajši od 18 let, saj možna tveganja in koristi niso znani.
The majority of patients had a primary diagnosis of back pain. 
Večina bolnikov je imelo primarno diagnozo bolečine v hrbtu.
Important notes: 
Pomembne opombe:
Studies have been conducted in juvenile rats and dogs. 
Študije so bile opravljene na mladičih podgan in psov.
How often this happens is not known from the data that is available. 
Ni znano, kako pogosto se je to zgodilo, saj podatki niso na voljo.
If it is not, do not use the solution. 
Če ni taka, je ne smete uporabiti.
Are you mobile enough to reach the toilet, or do you have a caregiver looking after you who can help? 
Ste dovolj pokretni, da lahko sami pridete do stranišča, oziroma imate negovalca, ki vam lahko pri tem pomaga?
This section is divided into the following subsections: 
To poglavje je razdeljeno v naslednja podpoglavja:
Has it been 48 hours or longer since your last bowel movement? 
Je od vašega zadnjega iztrebljanja minilo 48 ur ali več?
The injection volume for these patients should be calculated as follows: 
Injekcijski volumen za te bolnike izračunamo kot sledi:
Treatment should be initiated as appropriate. 
Z zdravljenjem je treba začeti, če je potrebno.
The following packs are available: 
Na voljo so naslednja pakiranja:
Wash your hands thoroughly with soap and warm water. 
Roke si temeljito umijte z milom in toplo vodo.
Date of first authorisation: 02 July 2008 Date of latest renewal: 27 May 2013 
Datum prve odobritve: 2. julij 2008 Datum zadnjega podaljšanja: 27. maj 2013
Please read and follow them step by step. 
Preberite jih in se korak za korakom ravnajte po njih.
Opioids are prescribed by your doctor. 
Opioide vam predpisuje vaš zdravnik.
There is no need to worry about this as it will not affect the accuracy of the dose or pose any risk to your health. 
Zaradi tega se ne vznemirjajte, saj to ne vpliva na natančnost odmerka in ne predstavlja tveganja za vaše zdravje.
This medicine is for use in adults (aged 18 and over). 
To zdravilo je namenjeno za uporabo pri odraslih (starih 18 let in več).
The terminal disposition half-life (t1/2) is approximately 8 hours. 
Končni razpolovni čas odstranjevanja (t1/2) je približno 8 ur.
Always have the outer carton of the medicine with you, even if it is empty. 
Vedno imejte pri sebi škatlo zdravila, tudi če je prazna.
Your doctor may allow you to take other medicines, including those used for constipation. 
Mogoče vam bo zdravnik dovolil jemati še druga zdravila, tudi taka, ki se uporabljajo za zaprtje.
You may have a bowel movement within a few minutes to a few hours of the injection; therefore, it is recommended to have a toilet facility or bedpan near you. 
Mogoče boste šli na blato v nekaj minutah do nekaj urah po injekciji; zato je priporočljivo, da imate stranišče ali nočno posodo v bližini.
When you hear a click sound that means the entire contents were injected. 
Potem ko zaslišite klik, to pomeni, da ste vbrizgali vso vsebino.
The following side effects are very common and may affect more than 1 in 10 people. 
Naslednji neželeni učinki so zelo pogosti in se lahko pojavijo pri več kot 1 od 10 bolnikov.
Please read the instructions carefully and follow them step by step. 
Navodila natančno preberite in se korak za korakom ravnajte po njih.
Avoid repeated injections at the exact same spot previously used. 
Izogibajte se ponovnim injekcijam na točno istem mestu, ki ste ga uporabili že prej.
If you receive only the vial, you will need to obtain alcohol swabs and an injection syringe. 
Če ste prejeli samo vialo, si boste morali nabaviti alkoholne zložence in injekcijsko brizgo.
In the event of an overdose, signs and symptoms of orthostatic hypotension should be monitored and reported to a physician. 
V primeru prevelikega odmerka je treba spremljati znake in simptome ortostatske hipotenzije in o njih poročati zdravniku.
The steady-state volume of distribution (Vss) is approximately 1.1 L/kg. 
Volumen porazdelitve v stanju ravnovesja (Vss) je približno 1,1 l/kg.
In both studies, there was no evidence to suggest differential effects of age or gender on safety or efficacy. 
V nobeni od teh dveh študij ni bilo znakov, ki bi kazali na razlikovalne učinke starosti ali spola na varnost ali učinkovitost.
You may receive either a pack containing an inner carton with everything needed for the injection, or a single vial only. 
Na voljo imate bodisi škatlo z notranjo škatlo, ki vsebuje vse, kar potrebujete za injiciranje, ali samo eno vialo.
However, this resulted in a small reduction in total clearance (from 107 L/h to 95 L/h). 
Vendar je to le malo zmanjšalo celotni očistek (s 107 l/uro na 95 l/uro).
This will mean that the safety mechanism has been activated, and the needle will disappear into the syringe. 
To bo pomenilo, da se je aktiviral varnostni mehanizem in igla se bo potegnila v injekcijsko brizgo.
Hold the syringe in one hand like a pencil. 
Držite brizgo v eni roki, kot bi držali svinčnik.
Therefore, no dose adjustment is recommended based on age. 
Zato na podlagi starosti ne priporočajo nikakršnega prilagajanja odmerjanja.
In these studies, the median age was 68 years (range 21-100); 51 % were females. 
V teh študijah je bila mediana starost 68 let (razpon 21-100); 51 % je bilo žensk.